Digital health company Noom on Thursday announced it will offer a compounded GLP-1 drug as part of a new weight loss product that starts at $149.
The treatment will feature compounded semaglutide, the same active ingredient in Novo Nordisk‘s blockbuster obesity and diabetes drugs Wegovy and Ozempic. Noom has offered weight loss programs for years, and consumers can already try to access those branded medications through its platform.
But Noom is the latest in a string of digital health companies to offer compounded versions of the medications as a cheaper alternative for consumers while demand for weight loss and diabetes drugs spikes. Hims & Hers and Sesame have launched similar programs in recent months — and the market for low-cost options has grown more competitive.
“Our position is that more supply, especially at a reasonable price, is needed right now, not less,” Noom CEO Geoff Cook told CNBC in an interview.
Wegovy and Ozempic belong to a highly popular class of medications called GLP-1s, which mimic certain gut hormones to tamp down a patient’s appetite and regulate their blood sugar. The compounded versions are custom-made alternatives to the brand drugs, and they can be produced when brand-name treatments are in shortage.
Compounded GLP-1 medications are typically much cheaper than their branded counterparts. Wegovy and Ozempic both cost roughly $1,000 per month before insurance. Most insurance plans cover GLP-1s when they are used to treat diabetes, but coverage of the weight loss drugs is less widespread. Spiking demand can also make it difficult for many patients to find the branded treatments.
Cook said consumers will pay $149 for their first month in Noom’s program and $279 for the following months as the dose of their medication increases.
The U.S. Food and Drug Administration does not review the safety and efficacy of compounded products, and the agency has urged consumers to take the approved, branded GLP-1 medications when they are available. However, the FDA does inspect some outsourcing facilities that compound drugs, according to its website.
Noom said it is working with an FDA-regulated 503B compounding pharmacy to provide its medication for its new program, which is called Noom GLP-1 RX.
“The drug manufacturer we’re working with generates 20 generic medications, epinephrine being one of them — a lifesaving medication that’s available in hospitals all across the United States,” Dr. Adonis Saremi, chief medical officer of Noom, told CNBC in an interview. “So we’re really confident and happy with our vetting process.”
The company said ithas also introduced a way for participants to taper off the compounded treatment if they would like to stop taking it. GLP-1s are intended for long-term use, which means some patients may end up taking them indefinitely.
Cook said Noom has seen both anecdotal and real-world evidence that patients are able to maintain weight loss after they stop taking the drugs. Six out of seven patients are off GLP-1s by the two-year mark anyway, he said.
“It’s prescribed by the doctor, the person takes their medicine, they lose weight, but then life happens,” Cook said. “They eventually stop taking the medication, or their insurance stops covering it, they’ll change a job [so] it’s no longer covered.”
Cook said not everyone will be able to taper off the medication, so some people will likely end up taking it indefinitely. The company will provide a free year of Noom or “substantial medication discounts” to anyone who regains the weight within 18 months after following its program for a year, it said in a release.
Consumers can get started with the Noom GLP-1 RX program by filling out an intake form on the website. Noom said one of its contracted, obesity-trained doctors will review the intake form and decide if the compounded medication is appropriate for that patient. If so, the drugs will arrive at their door within a week, Noom said.
Participants will learn how to inject their medication, and they can use a chat feature to talk one-on-one with a coach and their Noom clinician, the company said. They’ll also have access to a range of psychology-based programming and tools to help keep them from losing muscle mass, such as features for tracking protein intake and engaging in resistance training, Noom said.
And if users decide they are ready to move off the medication, they can chat with their clinician or tap “initiate taper” in their settings, Noom said.
“I think there’s a lot of folks who don’t want to be on a medication for the rest of their lives, and in any event, people aren’t doing that in the real world,” Cook said. “Our goal is just not to sell more medications. It’s to drive sustained weight loss outcomes.”
U.S. Treasury Secretary Scott Bessent and U.S. Trade Representative Jamieson Greer hold a press conference, following a meeting with Chinese Vice Premier He Lifeng, on the day of U.S.-China talks on trade, economic and national security issues, in Madrid, Spain, September 15, 2025.
Louiza Vradi | Reuters
Treasury Secretary Scott Bessent said Tuesday that President Donald Trump was willing to let TikTok go dark, and it was “what turned the tide” in the deal framework with China.
“President Trump made it clear that he would have been willing to let Tiktok go dark, that we were not going to give up national security in favor of the deal,” Bessent told CNBC’s “Squawk Box.”
TikTok parent company ByteDance is still looking at a Sept. 17 deadline to divest the app’s U.S. operations or potentially be shut down in the country.
The Trump administration hasn’t yet formally extended the deadline, though U.S. Trade Representative Jamieson Greer said Monday that more time may be needed for the deal to be finalized and signed.
Bessent said Tuesday that the commercial terms of the deal between ByteDance and the new investors had been done “in essence” since March or April.
After Trump’s massive tariff announcement on April 2, the Chinese put the deal on hold, he said.
Trump and Chinese President Xi Jinping are expected to speak Friday to finalize the deal.
“We were able to reach a series of agreements, mostly for things we will not be doing in the future that have no effect on our national security,” Bessent said Tuesday.
Read more CNBC tech news
This is breaking news. Please refresh for updates.
Meta CEO Mark Zuckerberg tries on Orion AR glasses at the Meta Connect annual event at the company’s headquarters in Menlo Park, California, U.S., September 25, 2024. REUTERS/Manuel Orbegozo
Manuel Orbegozo | Reuters
Meta spent billions of dollars unsuccessfully trying to make virtual reality catch on with consumers. As it shifts its metaverse bet toward smart glasses, investors will be watching to see how the public responds.
The social media company is set to unveil its most advanced smart glasses yet on Wednesday at its Connect annual event. The glasses, internally codenamed Hypernova, feature a small display that can be controlled via hand gestures through a wristband that utilizes neural technology, CNBC reported in August.
A promotional video of the device reportedly appeared on Meta’s YouTube page on Monday but was later removed.
The device, expected to cost $800, builds upon Meta’s partnership with EssilorLuxottica, which spawned the AI-powered Ray-Ban Meta smart glasses in 2023 and the Oakley Meta HSTN smart glasses unveiled in June. Those glasses contain cameras, speakers and microphones, allowing users to command the Meta AI voice assistant to take a photo, shoot video or play music.
Wall Street has been concerned about the spending by Reality Labs, the company’s division in charge of developing consumer hardware products like the Ray-Ban Meta glasses and the Quest VR headsets. Meta revealed in July that its Reality Labs division recorded an operating loss of $4.53 billion during the second quarter, and has totaled nearly $70 billion in losses since late 2020.
Investors understand that Meta’s Reality Labs spending won’t significantly pay off for years, but they also “want to see progress” that indicates they will “see potential returns on investment,” said Justin Post, a Bank of America Securities internet research analyst. For now, smart glasses seem like a more sound investment than VR headsets, which are still niche and could take years to blossom, he said.
“I’ve definitely seen the company’s focus shift from VR headsets to glasses,” Post said. “At this point, the glasses are going to be much more impactful and more mass market.”
Meta declined to comment.
In Hypernova, Meta is selling smart glasses with a display to consumers for the first time. Though that display is expected to be small and limited in what it shows to users, the release of Hypernova represents a middle ground between the Ray-Ban Meta glasses and the experimental Orion augmented reality glasses that Meta showed off during last year’s Connect event.
Meta’s Orion AR glasses are displayed during a viewing in Menlo Park, California, U.S., Sept. 26, 2024.
Manuel Orbegozo | Reuters
The Orion AR glasses, working in tandem with a wireless computing “puck,” can project 3D visuals onto the physical world that people can interact with using a wristband. But while the Orion AR glasses can produce dazzling visuals, it’s still experimental and costly to make, said Anshel Sag, a principal analyst at Moor Insights & Strategy.
“Delivering something like Orion at scale will take time, which is why they are still a prototype,” Sag said. “I think a single display is a move in the right direction and would help build an ecosystem of apps.”
Connect presents Meta with an opportunity to build off the unexpected success of the Ray-Ban Meta glasses, said Leo Gebbie, a CCS Insight analyst and director. EssilorLuxottica said in July, during the company’s most recent earnings report, that Ray-Ban Meta smart glasses sales more than tripled year over year.
“It really feels like a chance to break through with a really new product category,” Gebbie said.
Analysts will also be watching for any signs that Meta’s recent artificial intelligence-related strategy shifts, which kicked off in June when the company invested $14.3 billion into Scale AI, can help its hardware efforts. The glasses could be the right hardware form factor for AI features, Post said.
“If they get the integration right with devices, it really could be a better portal for AI than even phones,” he said.
But although Meta has the money and technical talent to build its smart glasses, it needs to cultivate an ecosystem of developers who will build compelling apps and software that captivate consumers, Sag said.
The risk for Meta is that consumers ultimately reject the Hypernova and potentially the broader market of smart glasses with displays, Gebbie said. At $800, the glasses are expected to cost more than twice as much as the Ray-Ban Meta glasses, which start at $299. Already, Meta is setting low internal expectations for sales of the Hypernova glasses, CNBC reported in August, but the company will want the unveiling to at least generate some buzz.
Meta’s ambition is for smart glasses to become the next major personal computing platform. For now, Apple and Google remain on top with the iOS and the Android mobile operating systems, respectively.
Apple declined to comment. Google didn’t respond to a request for comment.
It’s unclear if Meta’s glasses will ever usurp the smartphone’s standing with consumers, but there’s enough of a threat that both Apple and Google are working on their own competitive products. Apple is reportedly working on its own glasses project, and Google in May announced a $150 million partnership with Warby Parker to build smart glasses
“The fact that everyone is now developing glasses suggests that Meta’s Reality Labs concept was well conceived, and they’re out in front at this point on glasses,” said Post. “The question for the competition is, can they leverage their mobile operating systems to get people to buy their glasses?”
Tesla CEO Elon Musk attends the Saudi-U.S. Investment Forum, in Riyadh, Saudi Arabia, May 13, 2025.
Hamad I Mohammed | Reuters
Tesla’s shares have finally turned positive for the year.
After a dismal first quarter, which was the worst for the stock in any period since 2022, and a brutal start to April, following President Donald Trump’s announcement of sweeping new tariffs, Wall Street has again rallied around the electric vehicle maker.
The stock rose 3.6% on Monday to $410.26, topping its closing price of 2024 by over $6. It’s up 85% since bottoming for the year at $221.86 on April 4. A new filing revealed that CEO Elon Musk purchased about $1 billion worth of shares in the company through his family foundation.
It’s the second straight year Tesla has bounced back after a down first quarter. Last year, the shares fell 29% in the first three months before ending up 63% for 2024.
In recent weeks, analysts have praised the EV maker’s proposed pay plan for Musk, which could amount to a $1 trillion windfall for the world’s richest person over the next decade. The company has also gotten a boost from its new MegaBlocks battery energy storage systems that Tesla ships preassembled to businesses looking to lower their power costs or make greater use of electricity from renewable resources.
Even with the rebound, Tesla is the second-worst performer this year among tech’s megacaps, ahead of only Apple, which is down about 5% in 2025. Tesla is still in the midst of a multi-quarter sales slump due to an aging lineup of EVs and increased competition from lower-cost competitors in China, namely BYD.
Tesla has seen a consumer backlash, in part because of Musk’s political activities, including spending nearly $300 million to propel President Trump back to the White House and his work with the Trump administration to slash the federal workforce.
Tesla leadership has been working to shift investors’ attention to other topics such as robotaxis and humanoid robots.
However, the company has yet to deliver vehicles that are safe to use without a human onboard and ready to take control if needed. And while Musk is touting Tesla’s Optimus robots, which he says will be able to do everything from factory work to babysitting, a product is still a long way from hitting the market.